HIV mutation literature information.


  Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
 PMID: 30513108       2018       PLoS medicine
Abstract: At 48 weeks, the nucleoside reverse transcriptase inhibitor (NRTI) mutation K219E/Q (p = 0.004) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E/P (p = 0.03) and P225H (p = 0.007) were less common in virus from participants with raltegravir-intensified ART, with weak evidence of less interm
Discussion: Despite similar rates of virological failure >=1,000 copies/mL, raltegravir-intensified ART was associated with lower rates of the NRTI mutation K219E/Q and the NNRTI mutations K101E/P and P225H.


  Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.
 PMID: 30714528       2018       Current HIV research
Discussion: There are two clusters of TAMs; cluster 1 includes substitutions of M41L, L210W and T215Y, while cluster 2 of D67N, K70R, T125F and K219Q/E/N.


  Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.
 PMID: 30079168       2018       Journal of public health in Africa
Abstract: Other mutations such as T215F/Y, D67N/E, K70R, and K219Q were associated with intermediate resistance to TDF, AZT, and 3TC.
Result: Also, other DRM such as K70R (5.56%), K219Q (5.56%), T69D (5.56%), Y115F (5.56%) and K65R (5.56%) were detected with equal rates in mothers and were associated with resistance to (AZT, 3TC, TDF), 3TC, DDI, ABC and 3TC respectively.
Discussion: Others mutations detected such as T215F/Y, D67N/E, K70R, and K219Q are associated with intermediate resistance to TDF, AZT, and 3TC.


  Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
 PMID: 30442114       2018       BMC infectious diseases
Table: K219Q


  Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
 PMID: 30408827       2018       PloS one
Result: The thymidine analogue mutations (TAMs) M41L, K219Q and T215 revertants as well as the non-TAM M184V were among the most frequently transmitted NRTI-resistance mutations (>= 0.5%) (Table 4).
Table: K219Q


  Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
 PMID: 30223845       2018       Virology journal
Discussion: Generally, it is known that mutations selected by TAMS confer resistance to internationally approved NRTIs; examples of such TAMS encountered in the study are M41 L, D67N, K70R, L210 W, T215Y/F and K219Q/E.


  Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
 PMID: 30409215       2018       AIDS research and therapy
Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the RT, e.g., M41L, E44D, A62V, K65R, D67N, D67G, V75I, L100I, K103N, K103R, V188I, M184I, L210W, K219Q, Y318F, etc., although a number of minority mutations associated with resistance to PI (L10F, V11I, M46I/


  Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.
 PMID: 28333133       2017       Scientific reports
Introduction: Unlike HIV-1, HIV-2 does not develop resistance to nucleoside RT inhibitors (NRTIs) through the excision pathway (involving amino acid substitutions M41L, D67N, K70R, L210W, T215F/Y and K219E/Q in the viral RT), but relies exclusively on nucleotide discrimination.


  Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.
 PMID: 28099515       2017       PloS one
Table: K219Q


  Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
 PMID: 28365230       2017       EBioMedicine
Method: Because of the possibility that some individuals may have received a thymidine analog before receiving a TDF-containing regimen, as such switches may not have always reported, we excluded from our analysis individuals with sequences containing one or more canonical thymidine analogue mutations (TAMs) - M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E.



Browser Board

 Co-occurred Entities




   Filtrator